Seungil Han
Journal: Vitamins and hormones 2011;85():29-38
PMID: 21353874
Activin receptor type IIB (ActRIIB) belongs to a type II transforming growth factor-β (TGF-β) serine/threonine kinase receptor family which is integral to the activin and myostatin signaling pathway. Actvin and myostatin bind to activin type II receptors (ActRIIA and ActRIIB), and the glycine-serine-rich domains of type I receptors are phosphorylated by type II receptors. Activin enhances follicle-stimulating hormone biosynthesis and secretion and is involved in apoptosis, fibrosis, inflammation, and neurogenesis. Because of its essential role, activin is regarded as a novel drug target. Myostatin, also referred as growth and differentiation factor 8 (GDF-8), modulates skeletal muscle growth and has been a therapeutic target for disease conditions such as muscular dystrophy, sarcopenia, cashexia, and diabetes mellitus. The AcRIIB kinase domain from human represents a distinct type II receptor serine/threonine kinase subfamily identifiable in part by common features of Thr265 as a gatekeeper residue and back pocket supported by Phe247. The human ActRII kinase domain structure provides a basis for a more integrated understanding of substrate recognition and catalysis and will also be of help for developing chemical inhibitors.
Copyright © 2011 Elsevier Inc. All rights reserved.
Miscellaneous:
Full Text Sources:
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.